Description

Retatrutide (LY3437943) is an investigational research peptide characterized by activity at the GIP, GLP-1 and glucagon receptors. This triple-receptor profile distinguishes it from single-receptor GLP-1 compounds and dual GIP/GLP-1 receptor agonists.

For laboratory research use only. Not for human consumption, therapeutic use, or clinical use.

What Is Retatrutide?

Retatrutide, also known by the development designation LY3437943, is an investigational peptide designed to activate three metabolically relevant receptor systems: the GIP receptor, GLP-1 receptor, and glucagon receptor.

This triple-receptor profile distinguishes retatrutide from compounds that primarily target GLP-1 signaling alone and from dual-receptor compounds targeting GIP and GLP-1.

Retatrutide remains an investigational compound and should not be represented as an FDA-approved drug.

Retatrutide Specifications

Compound	Retatrutide
Development Name	LY3437943
CAS Number	2381089-83-2
Research Classification	Triple receptor agonist
Receptor Activity	GIP, GLP-1, and glucagon receptors
Physical Form	Lyophilized powder
Amount	10mg
Purity	99.2%
Analytical Testing	HPLC
Certificate of Analysis	View Current COA
Intended Use	Laboratory research only

Retatrutide Receptor Profile

The defining research characteristic of retatrutide is its activity across three receptor systems.

GIP Receptor

GIP is an incretin hormone involved in metabolic signaling and glucose-dependent biological processes. Retatrutide’s activity at the GIP receptor represents one component of its multi-receptor research profile.

GLP-1 Receptor

GLP-1 receptor signaling is widely studied in metabolic, endocrine, and glucose-regulation research. Retatrutide incorporates GLP-1 receptor activity alongside its GIP and glucagon receptor activity.

Glucagon Receptor

The addition of glucagon receptor activity differentiates retatrutide from single GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists.

This three-receptor architecture is why retatrutide is commonly described in scientific literature as a GIP, GLP-1, and glucagon receptor agonist.

Analytical Testing & Quality Verification

Analytical verification is an important component of peptide research because identity and purity cannot be reliably determined from appearance alone.

Inside Sciences provides batch-specific analytical documentation for qualifying research compounds.

HPLC Analysis

High-performance liquid chromatography (HPLC) can be used to evaluate peptide purity by separating components within a sample and measuring the relative chromatographic profile.

Retatrutide vs. Tirzepatide vs. Semaglutide

One of the most important distinctions among these compounds is their receptor profiles.

Compound	GLP-1	GIP	Glucagon	Research Classification
Semaglutide	Yes	No	No	GLP-1 receptor agonist
Tirzepatide	Yes	Yes	No	Dual GIP/GLP-1 receptor agonist
Retatrutide	Yes	Yes	Yes	Triple GIP/GLP-1/glucagon receptor agonist

These compounds should not be viewed simply as interchangeable versions of one another. Their receptor profiles and molecular characteristics differ, making them useful subjects for different areas of laboratory and metabolic research.

Read: Retatrutide vs. Tirzepatide Research Comparison

Read: Semaglutide vs. Tirzepatide vs. Retatrutide

Current Retatrutide Research

Retatrutide has progressed into late-stage clinical research and has been investigated as a GIP, GLP-1, and glucagon receptor agonist in metabolic research settings.

Its multi-receptor mechanism has made it an important subject for researchers studying incretin biology, metabolic signaling, and receptor interactions.

Inside Sciences does not represent clinical research findings as evidence supporting use of the research product sold on this page.

Retatrutide Research Resources

• Retatrutide Research Reference
• Retatrutide vs. Tirzepatide
• Semaglutide vs. Tirzepatide vs. Retatrutide
• GLP-1 & Multi-Receptor Research Hub
• Understanding HPLC Peptide Analysis

Frequently Asked Questions

What is Retatrutide?

Retatrutide is an investigational peptide, also known as LY3437943, characterized by activity at the GIP, GLP-1, and glucagon receptors.

What is Retatrutide’s CAS number?

Retatrutide is commonly identified by CAS number 2381089-83-2.

What receptors does Retatrutide target?

Retatrutide has been developed as a triple agonist targeting the GIP, GLP-1, and glucagon receptors.

How is Retatrutide different from Tirzepatide?

Tirzepatide targets GIP and GLP-1 receptors, while retatrutide incorporates activity at GIP, GLP-1, and glucagon receptors.

How is Retatrutide different from Semaglutide?

Semaglutide is characterized as a GLP-1 receptor agonist, whereas retatrutide has activity across GIP, GLP-1, and glucagon receptors.

Is Retatrutide FDA approved?

Retatrutide remains investigational and should not be represented as an FDA-approved drug.

What is Inside Sciences Retatrutide intended for?

Inside Sciences Retatrutide is supplied for laboratory research purposes only. It is not intended for human consumption, therapeutic use, diagnostic use, or clinical use.

---

Research Use Only: This product is intended strictly for laboratory research purposes. It is not intended for human consumption, therapeutic use, diagnostic use, or use as a drug, food, or cosmetic product.